MedTrace Logo

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

NCT00751062 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2021-02-02

No results posted yet for this study

Summary

PhXA41 is not inferior to timolol in reducing intra-ocular pressure

Conditions

Interventions

DRUG

timolol

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.

DRUG

PhXA41

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-11-30
Primary Completion
1993-12-31
Completion
1993-12-31

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751062 on ClinicalTrials.gov